Researchers, led by Professor David R. Liu, say that their approach — dubbed “phage-assisted continuous evolution,” or PACE — is roughly 100 times faster than conventional laboratory evolution, and far less labor-intensive for scientists. Scientists at Harvard University have harnessed the prowess of fast-replicating bacterial viruses, also known as phages, to accelerate the evolution of biomolecules in the laboratory. The work, reported in the journal Nature, could ultimately allow the tailoring of custom pharmaceuticals and research tools from lab-grown proteins, nucleic acids, and other such compounds.
“Most modern drugs are based on small organic molecules, but biological macromolecules may be better suited as pharmaceuticals in some cases,” said Liu, a professor of chemistry and chemical biology at Harvard and an investigator with the Howard Hughes Medical Institute. “Our work provides a new solution to one of the key challenges in the use of macromolecules as research tools or human therapeutics: how to rapidly generate proteins or nucleic acids with desired properties.”
Liu and Harvard co-authors Kevin M. Esvelt and Jacob C. Carlson achieved up to 60 rounds of protein evolution every 24 hours by linking laboratory evolution to the life cycle of a virus that infects bacteria. This phage’s life cycle of just 10 minutes is among the fastest known. Because this generation time is so brief, the phage makes a perfect vehicle for accelerated protein evolution. The PACE system uses E. coli host cells to produce the resulting proteins, to serve as factories for phage production, and to perform the key selection step that allows phage-carrying genes encoding desired molecules to flourish.
In three protein evolution experiments, PACE was able to generate an enzyme with a new target activity within a week, achieving up to 200 rounds of protein evolution during that time. Conventional laboratory evolution methods, Liu said, would require years to complete this many rounds of evolution.
Evolution of biomolecules is also a natural process, of course. But during biological evolution, generation times tend to be long, and researchers have no control over the outcomes. Laboratory evolution (also called directed evolution) has been practiced for decades to generate biomolecules with tailor-made properties, but it typically proceeds at a rate of about one round of evolution every few days and requires frequent sample manipulation by scientists or technicians during that time.
In addition to not requiring human intervention during the evolutionary process, Liu’s new approach uses readily available components and is designed to be resistant to “cheater” molecules that bypass the desired selection process. Researchers can control PACE’s “selection stringency” as well as its mutation rate.
“Laboratory evolution has generated many biomolecules with desired properties, but a single round of mutation, gene expression, screening or selection, and replication typically requires days or longer with frequent human intervention,” Liu, Esvelt, and Carlson wrote in Nature. “Since evolutionary success is dependent on the total number of rounds performed, a means of performing laboratory evolution continuously and rapidly could dramatically enhance its effectiveness.”
Over the past several years we have developed a continuous directed evolution system that in principle can be applied to evolve a wide variety of protein and nucleic acid binding and catalytic activities. Our continuous evolution system can support more than 100 rounds of evolution (complete cycles of translation, selection, amplification, and mutation) per 24 hours. It is self-sustaining and requires no human intervention during evolution, and therefore no transformation, screening, or user mediated gene manipulation. The system is also resistant to error catastrophe or to takeover by “cheaters” that have acquired mutations in genes others than the one(s) of interest. Finally, our continuous evolution system is accessible to laboratories other than our own and requires only minimal assembly from commercially available parts. Very recently, we applied this system to successfully evolve RNA polymerase enzymes with altered promoter specificities through over 50 rounds of evolution in ~24 hours. These early results suggest the ability of this continuous directed evolution system to rapidly evolve a protein with no discrete library creation, transformation, cloning, or screening steps. Efforts are underway to apply continuous evolution to a wide variety of protein and nucleic acid activities.
Development of Supercharged Proteins for Protein Engineering and Macromolecule Delivery
The outcome of screening variants of a highly aggregation-prone computationally designed protein for mutants that resist aggregation led us to hypothesize that the extensive mutation of surface-exposed residues from neutral amino acids to charged amino acids can dramatically reduce a protein’s tendency to aggregate without abolishing the protein’s structure or function. We tested this hypothesis by mutating virtually all non-conserved surface exposed residues of several different proteins to Lys or Arg, creating “superpostive” proteins, or to Asp or Glu, creating “supernegative proteins”. We discovered that the resulting “supercharged” proteins can retain their native folding and function (including catalytic activity), but are virtually immune to spontaneous aggregation, chemically induced aggregation, or thermally induced aggregation.
If you liked this article, please give it a quick review on ycombinator or StumbleUpon. Thanks
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.